NASDAQ:DCPHDeciphera Pharmaceuticals Stock Price, Forecast & News

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DCPH stock has increased by 33.3% and is now trading at $59.23. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) issued its quarterly earnings results on Tuesday, May, 5th. The company reported ($1.36) EPS for the quarter, missing the Zacks' consensus estimate of ($1.28) by $0.08. The company earned $0.06 million during the quarter, compared to analysts' expectations of $2.50 million. View Deciphera Pharmaceuticals' earnings history.

16 equities research analysts have issued 1 year price targets for Deciphera Pharmaceuticals' shares. Their forecasts range from $42.00 to $91.00. On average, they expect Deciphera Pharmaceuticals' stock price to reach $68.06 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price. View analysts' price targets for Deciphera Pharmaceuticals.

Media stories about DCPH stock have trended very positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Deciphera Pharmaceuticals earned a news impact score of 4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutDeciphera Pharmaceuticals.

Some companies that are related to Deciphera Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Catalent (CTLT), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN), Perrigo (PRGO), Ascendis Pharma A/S (ASND) and Bausch Health Companies (BHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), Allena Pharmaceuticals (ALNA), Viking Therapeutics (VKTX), GW Pharmaceuticals PLC- (GWPH), Immunomedics (IMMU), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), AbbVie (ABBV), Bausch Health Companies (BHC) and Cytokinetics (CYTK).

(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Deciphera Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Redmile Group LLC (9.16%), Franklin Resources Inc. (5.80%), BlackRock Inc. (3.81%), ArrowMark Colorado Holdings LLC (3.02%), Alliancebernstein L.P. (2.26%) and Orbimed Advisors LLC (2.07%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly. View institutional ownership trends for Deciphera Pharmaceuticals.

DCPH stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Orbimed Advisors LLC, Capital World Investors, Lord Abbett & CO. LLC, Pictet Asset Management Ltd., Casdin Capital LLC, Cormorant Asset Management LP, and Rock Springs Capital Management LP. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen, and Thomas Patrick Kelly. View insider buying and selling activity for Deciphera Pharmaceuticals.

DCPH stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Redmile Group LLC, Eventide Asset Management LLC, TimesSquare Capital Management LLC, Sphera Funds Management LTD., Two Sigma Advisers LP, BlackRock Inc., and Emerald Advisers LLC. View insider buying and selling activity for Deciphera Pharmaceuticals.

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DCPH stock can currently be purchased for approximately $59.23.

Deciphera Pharmaceuticals has a market capitalization of $3.31 billion and generates $25 million in revenue each year. The company earns $-192,260,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.

The official website for Deciphera Pharmaceuticals is www.deciphera.com.

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]